Trial · NCT03372057
Adverse events648
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 648
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Dose Optimization Phase: Cohort 1 | 7 | 20 | |
| other | Anaemia | Blood and lymphatic system disorders | Dose Optimization Phase: Cohort 2 | 5 | 13 | |
| other | Anaemia | Blood and lymphatic system disorders | Expansion Phase | 34 | 123 | |
| other | Autoimmune haemolytic anaemia | Blood and lymphatic system disorders | Dose Optimization Phase: Cohort 1 | 0 | 20 | |
| other | Autoimmune haemolytic anaemia | Blood and lymphatic system disorders | Dose Optimization Phase: Cohort 2 | 1 | 13 | |
| other | Autoimmune haemolytic anaemia | Blood and lymphatic system disorders | Expansion Phase | 0 | 123 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Dose Optimization Phase: Cohort 1 | 0 | 20 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Dose Optimization Phase: Cohort 2 | 0 | 13 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Expansion Phase | 7 | 123 | |
| other | Normocytic anaemia | Blood and lymphatic system disorders | Dose Optimization Phase: Cohort 1 | 0 | 20 | |
| other | Normocytic anaemia | Blood and lymphatic system disorders | Dose Optimization Phase: Cohort 2 | 1 | 13 | |
| other | Normocytic anaemia | Blood and lymphatic system disorders | Expansion Phase | 0 | 123 | |
| other | Sinus tachycardia | Cardiac disorders | Dose Optimization Phase: Cohort 1 | 1 | 20 | |
| other | Sinus tachycardia | Cardiac disorders | Dose Optimization Phase: Cohort 2 | 2 | 13 | |
| other | Sinus tachycardia | Cardiac disorders | Expansion Phase | 7 | 123 | |
| other | Tachycardia | Cardiac disorders | Dose Optimization Phase: Cohort 1 | 1 | 20 | |
| other | Tachycardia | Cardiac disorders | Dose Optimization Phase: Cohort 2 | 2 | 13 | |
| other | Tachycardia | Cardiac disorders | Expansion Phase | 4 | 123 | |
| other | Ear discomfort | Ear and labyrinth disorders | Dose Optimization Phase: Cohort 1 | 0 | 20 | |
| other | Ear discomfort | Ear and labyrinth disorders | Dose Optimization Phase: Cohort 2 | 1 | 13 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03372057/events